Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-IMG-131539

Xenbase Image ID: 131539


Fig. 8. Additive effects of Xvent genes in gainand loss-of-function. (A) Xvent genes ventralize mesoderm in an additive fashion. Embryos were either non-injected (Co) or microinjected radially at the 4- to 8-cell stage with Xvent-1 (range 0.125-0.25 ng/blastomere) or Xvent-2 mRNA (range 0.37-075 ng/blastomere), or injected with a mixture (same range of both). The average dorsoanterior index (Kao and Elinson, 1988) of embryos was 4.8 (uninjected control, n=22), 4.4 (Xvent-1, n=34), 3.0 (Xvent- 2, n=47) and 2.6 (Xvent-1 + Xvent-2, n=33). (B) Xvent genes function in an additive fashion in downregulation of dorsal and upregulation of ventral marker genes in DMZ. Embryos were either non-injected (Co), or microinjected radially at the 4- and 8-cell stage with the doses indicated in ng/blastomere with Xvent-1 or Xvent-2 mRNAs, or injected with a mixture. Control (Co) VMZ and DMZs were explanted at early gastrula stage and fixed immediately for total RNA preparation. Expression of marker genes indicated was assayed by RT-PCR. (C) VPXvent-1/2 mRNA injections induce dorsal marker genes additively. Embryos were either non-injected (Co), or microinjected radially at the 4- to 8-cell stage with the doses indicated in ng/blastomere with VPXvent-1 or VPXvent-2 mRNAs, or injected with a mixture. Control (Co) DMZ and VMZs were explanted at early gastrula stage and fixed immediately for total RNA preparation. Expression of marker genes indicated was assayed by RT-PCR. Histone H4 was used for normalisation.

Image published in: Onichtchouk D et al. (1998)

Copyright © 1998. Image reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.

Larger Image
Printer Friendly View

Return to previous page